Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.

ABSTRACT:

Background

The overall prognosis of non-small cell lung cancer (NSCLC) is poor, and currently only patients with localized disease are potentially curable. Therefore, preferably non-invasively determined biomarkers that detect NSCLC patients at early stages of the disease are of high clinical relevance. The aim of this study was to identify and validate novel protein markers in plasma using the highly sensitive DNA-assisted multiplex proximity extension assay (PEA) to discriminate NSCLC from other lung diseases.

Methods

Plasma samples were collected from a total of 343 patients who underwent surgical resection for different lung diseases, including 144 patients with lung adenocarcinoma (LAC), 68 patients with non-malignant lung disease, 83 patients with lung metastasis of co

SUBMITTER: Djureinovic D 

PROVIDER: S-EPMC6664554 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature